Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
976 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
| NCT04464174 | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer(PATHFINDER) | completed | Phase 2 | 54 | MedSIROTHER | 2 | Jul 26, 2024 |
| clinicaltrials |
| NCT03306394 | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).(PRECONNECT) | completed | Phase 3 | 907 | Institut de Recherches Internationales ServierOTHER | 16 | Jul 25, 2024 | clinicaltrials |
| NCT04763408 | A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma(STELLAR) | completed | — | 335 | Eisai Inc.INDUSTRY | 10 | Jul 18, 2024 | clinicaltrials |
| NCT01660451 | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | completed | Phase 2 | 227 | BayerINDUSTRY | 25 | Jul 17, 2024 | clinicaltrials |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas(GAMMA) | completed | Phase 3 | 800 | NantCell, Inc.INDUSTRY | 32 | Jul 16, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT04128696 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-3) | terminated | Phase 3 | 315 | GlaxoSmithKlineINDUSTRY | 26 | Jul 10, 2024 | clinicaltrials |
| NCT06429189 | Home-Combo: an Online Home-based Combined Exercise Intervention for Women With Breast Cancer | unknown | N/A | 98 | Grupo LusófonaOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT03710486 | A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants(EVOLVE-IBERIA) | completed | — | 409 | TakedaINDUSTRY | 2 | May 30, 2024 | clinicaltrials |
| NCT03920293 | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | completed | Phase 3 | 175 | Alexion Pharmaceuticals, Inc.INDUSTRY | 15 | May 28, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT02573584 | Vascular Fingerprint Validation Study | completed | — | 101 | University Medical Center GroningenOTHER | 3 | May 17, 2024 | clinicaltrials |
| NCT06371118 | HPV Self-sampling for Women Who do Not Attend Cervical Cancer Screening Programme(HERSELF) | unknown | N/A | 1,000 | Universidade do PortoOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03957031 | Gastric Cancer Risk Factors Associated With EU and CELAC Populations(LEGACY-1) | completed | — | 1,600 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 7 | May 9, 2024 | clinicaltrials |
| NCT04015466 | Advanced GC Multi-omic Characterization in EU and CELAC Populations(LEGACY-2) | completed | — | 800 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 7 | May 9, 2024 | clinicaltrials |
| NCT04019808 | Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population(LEGACY-3) | completed | — | 800 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 7 | May 9, 2024 | clinicaltrials |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | terminated | Phase 3 | 48 | QED Therapeutics, a BridgeBio companyINDUSTRY | 15 | May 8, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT06394258 | POSE - POs Surgery Endometrial Cancer(POSE) | completed | N/A | 30 | Fundacao ChampalimaudOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06394297 | VIBE - Virtual Image Guided Brachytherapy Emulation for Locally Advanced Cervical Cancer (LACC)(VIBE) | unknown | N/A | 30 | Fundacao ChampalimaudOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT03935763 | Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective(PROMETCO) | unknown | — | 738 | Servier Affaires MédicalesINDUSTRY | 18 | Apr 22, 2024 | clinicaltrials |
| NCT06007001 | Telerehabilitation and Tele-psychological Support in Cancer Patients eCAN JA(eCAN) | unknown | N/A | 354 | SciensanoOTHER_GOV | 10 | Apr 19, 2024 | clinicaltrials |
| NCT06371807 | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab(KEYPARTNER) | not yet recruiting | Phase 2 | 20 | Fundacao ChampalimaudOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT01942135 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | completed | Phase 3 | 521 | PfizerINDUSTRY | 17 | Apr 4, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT04768218 | BLI for the Diagnosis of Precancerous Conditions | completed | — | 102 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT02603432 | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) | completed | Phase 3 | 700 | PfizerINDUSTRY | 29 | Mar 27, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT05237921 | Adherence to Exercise and Dietary Intervention in Cancer Patients(CEDI) | completed | N/A | 50 | Hospital Beatriz ÂngeloOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05420259 | Combined Exercise and Nutritional Intervention in GI Cancer Patients | unknown | N/A | 68 | Hospital Beatriz ÂngeloOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(MONALEESA-7) | completed | Phase 3 | 672 | Novartis PharmaceuticalsINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT03321981 | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. | completed | Phase 2 | 105 | Merus B.V.INDUSTRY | 7 | Mar 7, 2024 | clinicaltrials |
| NCT00330447 | Effects of Oncological Treatment During Pregnancy on Mother and Child | recruiting | — | 5,000 | University Hospital, GasthuisbergOTHER | 20 | Mar 6, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT05946161 | Testing an e-Health Intervention for Prostate Cancer Survivors' Mental and Sexual Health | unknown | N/A | 30 | Universidade do PortoOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03694522 | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer(FIGHT) | completed | Phase 2 | 155 | Five Prime Therapeutics, Inc.INDUSTRY | 18 | Feb 28, 2024 | clinicaltrials |
| NCT06254300 | Online Exercise Program During Perioperative Treatment in Adults With Gastric Cancer(On4Cancer) | unknown | N/A | 40 | University of MaiaOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT01802814 | International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 | completed | Phase 3 | 700 | Charite University, Berlin, GermanyOTHER | 17 | Feb 9, 2024 | clinicaltrials |
| NCT06212414 | Mind Programme for Women With Breast Cancer (Nationwide Coverage)(MIND(n)) | unknown | N/A | 153 | University of CoimbraOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03674112 | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer(PHranceSCa) | completed | Phase 2 | 160 | Hoffmann-La RocheINDUSTRY | 17 | Jan 2, 2024 | clinicaltrials |
| NCT05444972 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review(METER) | completed | — | 998 | AbbVieINDUSTRY | 14 | Dec 11, 2023 | clinicaltrials |
| NCT02422615 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-3) | completed | Phase 3 | 726 | Novartis PharmaceuticalsINDUSTRY | 30 | Nov 30, 2023 | clinicaltrials |
| NCT05270044 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.(COLUMBUS-AD) | active not recruiting | Phase 3 | 815 | Pierre Fabre MedicamentINDUSTRY | 23 | Nov 22, 2023 | clinicaltrials |
| NCT06143189 | Well-being Biomarkers (BIOSMILE) & Psychology Analyses in Women With Cancer After Hospital Clowns and Hosting Effects | completed | N/A | 64 | University of CoimbraOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06136702 | ELEVATE Acceptability Study(ELEVATE AS) | unknown | N/A | 1,048 | University GhentOTHER | 4 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials